Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 Berlin (Germany), April 30, 2024 - Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024 due to the successful transfer of nearly all a [ … ]

Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 Berlin (Germany), April 30, 2024 - Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024 due to the successful transfer of nearly all a [ … ]

Epigenomics AG publishes financial results for fiscal year 2023 Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023. OPERATIONAL DEVELOPMENTS Due to the lack of necessary financing for the further development of the Epi proColon “Next-Gen” test and t [ … ]

Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Bo [ … ]

Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board Berlin, January 31, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the "Company"), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that the Supervisory  [ … ]

Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD) Berlin, Germany, January 26, 2024 – Dr Heikki Lanckriet (PhD) has informed the competent bodies of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”) that he resigned as a member of the Company's Supervisory Board with effect as of 22 February 2024. The [ … ]